Rebranding generics as branded medicines – CJEU issues new guidance

Written By

heidi hurdle Module
Heidi Hurdle

Professional Support Lawyer
UK

I am the Professional Support Lawyer to Bird & Bird's market-leading Intellectual Property group in London.

The CJEU has provided welcome new guidance on when parallel importers can rebrand generic medicines with the original trade mark of the reference medicinal product.

Its ruling in Impexeco NV v Novartis AG and PI Pharma NV v Novartis AG (Joined cases C 253/20 and C 254/20) is one of series of landmark judgments concerning parallel imports of pharmaceuticals released by the CJEU last month. (See our article here for details of these other judgments which put parallel imports and new anti-tampering devices under the spotlight.)

Full article available on BioTalk. Read more here

Latest insights

More Insights
Curiosity line yellow background

Hong Kong’s Clinics to Prepare for Licensing Regime

Aug 13 2025

Read More
featured image

Women in Tech: At the forefront of innovation - Key takeaways from Dana Ghosn, Typeless

3 minutes Aug 07 2025

Read More
featured image

German Constitutional Court upholds pharmaceutical cost control measures: implications for drug pricing and reimbursement

5 minutes Aug 05 2025

Read More